CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell. After that ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

A research team headed by the University of Zurich has developed a powerful new method to precisely edit DNA by combining ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like sickle ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, ...

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of ...

If you have been watching CRISPR Therapeutics (CRSP) lately, you have probably noticed the sharp rebound in its stock price. The rally was set off by compelling developments, specifically Casgevy’s ...

Mars partners with Pairwise to use CRISPR tech for developing disease- and climate-resilient cacao, aiming to secure future ...

CRISPR Therapeutics is expected to post a loss of $1.31 per share for the current quarter, representing a year-over-year change of +8.4%. Over the last 30 days, the Zacks Consensus Estimate has ...

CRISPR Therapeutics is expected to post a loss of $1.54 per share for the current quarter, representing a year-over-year change of -3.4%. Over the last 30 days, the Zacks Consensus Estimate has ...